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Abstract Cardiac stress can induce morphological,
structural and functional changes of the heart, referred to as
cardiac remodeling. Myocardial infarction or sustained
overload as a result of pathological causes such as hyper-
tension or valve insufficiency may result in progressive
remodeling and finally lead to heart failure (HF). Whereas
pathological and physiological (exercise, pregnancy)
overload both stimulate cardiomyocyte growth (hypertro-
phy), only pathological remodeling is characterized by
increased deposition of extracellular matrix proteins, ter-
med fibrosis, and loss of cardiomyocytes by necrosis,
apoptosis and/or phagocytosis. HF is strongly associated
with age, and cardiomyocyte loss and fibrosis are typical
signs of the aging heart. Fibrosis results in stiffening of the
heart, conductivity problems and reduced oxygen diffusion,
and is associated with diminished ventricular function and
arrhythmias. As a consequence, the workload of car-
diomyocytes in the fibrotic heart is further augmented,
whereas the physiological environment is becoming less
favorable. This causes additional cardiomyocyte death and
replacement of lost cardiomyocytes by fibrotic material,
generating a vicious cycle of further decline of cardiac
function. Breaking this fibrosis-cell death axis could halt
further pathological and age-related cardiac regression and
potentially reverse remodeling. In this review, we will
describe the interaction between cardiac fibrosis, car-
diomyocyte hypertrophy and cell death, and discuss
potential strategies for tackling progressive cardiac
remodeling and HF.
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Heart failure and cardiac remodeling
Fibrosis is the excessive deposition of extracellular matrix
(ECM), such as collagens and fibronectin, resulting in the
excessive accumulation of fibrous connective tissue [1, 2].
Fibrosis is an essential process in the repair of damaged
tissues and wounds, but its accumulation in organs and
tissues can lead to scarring, organ dysfunction and, ulti-
mately, failure. In many chronic diseases, sustained pro-
gressive fibrosis can be very detrimental, like in fibrotic
kidney and liver disease, and this is also true for chronic
heart failure [3]. Heart failure (HF) is a complex clinical
syndrome in which reduced cardiac function results in
insufficient perfusion of peripheral tissues [4, 5]. HF is an
enormous health problem in the Western society, in which
more than 8 % of the population aged 75 years and older
are diagnosed with HF, and prevalence and incidence rates
are not expected to decline in the upcoming decade [6].
Cardiac remodeling, which can be described as any struc-
tural and functional change of the heart, underlies HF
development. Cardiac remodeling is a reaction of the heart
to reduce ventricular wall stress in response to changes in
after load (pressure load), preload (volume overload) or
myocardial injury [7]. Amongst others, main risk factors
for HF include coronary artery disease and hypertension
[6]. A recent study of a community-based cohort revealed
that more than 70 % of new HF patients had a history of
hypertension and more than 25 % have had a preceding
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myocardial infarction (MI) [8]. Regardless of the initiating
events, cardiac hypertrophy, cardiomyocyte cell death and
fibrosis constitute key features of pathological cardiac
remodeling.
Fibrosis is a hallmark of pathological cardiac remodeling
and is absent under physiological stress conditions, such as
exercise and pregnancy [9–11]. Cardiac fibrosis appears to
be an irreversible process [12] and is increasingly recognized
as a major cause of morbidity and mortality in many chronic
diseases. In the myocardium, fibrosis can be divided into
interstitial fibrosis, replacement fibrosis and perivascular
fibrosis, which all have their characteristics (Fig. 1). The
distinction between different types of fibrosis is made based
on cause and anatomical localization [13]. As a response to
increased wall stress generated by a cardiac stressor, like
hypertension, interstitial reactive fibrosis is developed in the
myocardium [14, 15]. Reactive interstitial fibrosis is located
in the ECM surrounding cells and is defined as the expansion
of ECM without cardiomyocyte loss and is characterized by
a widespread deposition of collagens throughout the myo-
cardium [13, 14]. In perivascular fibrosis, which is also
associated with hypertension, fibrillar collagens accumulate
in the adventitia of intramural coronary arteries [14, 16, 17].
With ongoing hypertension, the accumulation of collagens
progresses [17].
Replacement fibrosis occurs in themyocardium to replace
dead tissue and is an essential repair process aftermyocardial
infarction [13, 14, 16, 18]. Since cardiomyocytes have no or
only very limited proliferative capacity, cardiomyocyte
replacement does not occur in the damaged heart and scar
formation is the only reparative mechanism to prevent car-
diac rupture. Replacement fibrosis does also occur under
other pathological conditions that will ultimately affect
cardiomyocyte viability, like in sustained hypertension,
cardiomyopathies and valve insufficiencies. This may result
in a more dispersed fibrosis throughout the myocardium.
Thus, fibrosis may initially have cardiac preserving
functions, but a sustained fibrotic response, as observed
under pathological conditions, may negatively impact on
cardiac function and finally exacerbate cardiac functional
decline. Persistent accumulation of collagens disturbs tis-
sue architecture, stiffens the heart and can affect both
systolic and diastolic function and contribute to arrhyth-
mias [17]. In agreement with this hypothesis, Hein et al.
[19] observed in aortic stenosis patients with HF an
increase in fibrosis and cell death. This was strongly
increased in decompensated patients in whom fibrosis and
myocyte degeneration was strongly accelerated [19]. These
observations support the view that an apparent vicious
cycle of impaired cardiac function, fibrogenesis and cell
death exists and if not properly treated this cycle will
accelerate and result in cardiac failure [19]. Not surpris-
ingly, fibrosis-associated proteins, including soluble sup-
pression of tumorigenicity 2 (sST2) and galectin-3 (Gal-3),
which can be detected in blood plasma, are increasingly
recognized as markers for poor prognosis of HF patients
[20–23]. These biomarkers have recently been included in
the AHA/ACC clinical guidelines for potential additive
risk stratification of patients with established HF [5].
Nevertheless, additional research will be required to prove
that circulating biomarkers properly reflect histological
myocardial fibrosis [24].
In contrast to cardiac fibrosis, hypertrophy is generally
believed to be an adaptive and protective mechanism since
it also occurs in athletes and pregnant women [9–11]. This
physiological hypertrophy is reversible and does not
Fig. 1 Different types of fibrosis. Mouse cardiac tissue was stained
with Masson’s trichrome stain to visualize cardiomyocytes in red and
fibrotic fibers in blue. Pictures with interstitial and perivascular
fibrosis are from pressure overload (TAC) mouse hearts and
replacement fibrosis from mouse hearts with a myocardial infarction.
Bar indicates 50 lm
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decompensate to HF. Sustained wall stress associated with
cardiovascular diseases generates, however, a pathological
form of hypertrophy, which is associated with reduced
cardiomyocyte function. Among others, pathological
hypertrophy involves alterations in Ca2? handling,
increased oxidative stress, changes in excitation–contrac-
tion coupling, sarcomere dysfunction and metabolic and
energetic remodeling [9–11]. These cellular and molecular
changes finally culminate into cardiomyocyte death caused
by necrosis, apoptosis and/or phagocytosis [9, 25, 26].
Importantly, myofibroblasts, which are the main producers
of ECM components, also secrete numerous factors with
inflammatory and paracrine functions and play an essential
role in hypertrophy development under pathological con-
ditions. The contribution of myofibroblasts toward cardiac
dysfunction is therefore twofold, namely via connective
tissue formation and via production of paracrine and
inflammatory molecules [27, 28]. Together, this will pro-
mote pathological cardiomyocyte hypertrophy and may
finally lead to cardiomyocyte death and progressive dete-
rioration of cardiac function. Excellent reviews have been
published on apoptosis (programmed cell death), necrosis
and phagocytosis, and we will not elaborate on these and
other modes of cell death [26, 29–31]. Here, we will review
the deleterious effects of activated (myo)fibroblast on
cardiac function and postulate an apparent vicious cycle of
fibrogenesis, impaired cardiac function and cardiomyocyte
cell death (Fig. 2).
Cardiac fibroblasts and myofibroblasts
In the healthy heart, normal amounts of fibrillar collagens
form a network between different cell types within the
myocardium and are essential to provide a scaffold for
myofiber alignment and to maintain cardiac geometry
during systole and diastole of the heart. Collagen I and III
are the main collagens in the heart and constitute about 85
and 10 % of collagen, respectively [16]. Fibroblasts, which
constitute the majority of the large (40–70 %) non-my-
ocyte population in the heart [32–34] are responsible for
the turnover of ECM proteins and play an essential role in
maintaining the integrity of connective tissue. It is gener-
ally believed that most cardiac fibroblasts in the myo-
cardium are derived from the pericardium during
development, but proper fait mapping is still lacking [34].
Fibroblasts are a heterogeneous group of cells, and so far
no specific markers have been identified for fibroblasts.
Discoidin domain receptor 2 (DDR2), a tyrosine kinase cell
surface receptor for collagen [35], has been predominantly
used to define fibroblast in the heart [33]. DDR2 is also
expressed in other cells outside the heart, and among
Fig. 2 A simplified depiction
of the vicious cycle of
myofibroblast activation,
impaired cardiac function and
cardiomyocyte cell death. This
simplified scheme shows in the
outer circle (black) the role of
myofibroblasts in fibrogenesis
and cardiac impairment,
whereas the inner processes
predominantly reflect paracrine
signaling effects. Together, this
generates a sustained response
of progressive cardiac
deterioration. FMT fibroblasts to
myofibroblasts transition, IL-6
interleukin-6, IL-33 interleukin-
33, FGF2 fibroblast growth
factor 2, TGFb transforming
growth factor beta. Lightning
symbols indicate stressors acting
on the cells
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others, it is important for chondrocyte proliferation [36].
Thus, although it may specify fibroblasts in the heart, it is
not a specific fibroblast marker in general.
A common feature to fibrotic diseases is the activation
of fibroblasts and their differentiation into myofibroblasts,
which express and secrete much higher levels of ECM
proteins. Myofibroblasts are not usually present in healthy
cardiac tissue, with the exception of heart valve leaflets.
Fibroblasts to myofibroblasts transition (FMT) can be
induced by mechanical stress, cytokines, growth factors
and ECM components [37]. Transforming growth factor b
(TGFb) is the most potent activator of FMT. Three
homologues of TGFb isoforms exist (TGFb1, TGFb2,
TGFb3) in mammalians that are produced as latent pre-
cursors bound to latency-associated peptide (LAP), which
can interact with latent TGFb-binding proteins (LTBP1–4)
to form a large latent complex (LLC) that is effectively
secreted into the extracellular space. Only after cleavage of
this complex by extracellular proteases, TGFb becomes
liberated and can bind to its cellular receptor [38, 39].
TGFb signals via a heteromeric tyrosine kinase complex of
TGFb type I receptor (TGFBR1, also termed Alk5) and
type II receptor (TGFBR2), in which TGFBR2 phospho-
rylates TGFBR1, which propagates the signal via activa-
tion of SMAD transcription factors. This results in
relocalization of the SMAD2/SMAD3 to the nucleus and
the expression of ECM matrix proteins and alpha-smooth
muscle actin (aSMA) [40]. The latter is used as a marker to
identify myofibroblasts, although it is not specific and is
also strongly expressed in smooth muscle cells [41]. aSMA
allows contraction of myofibroblasts [42], and this is
important during wound closure, but in the heart it can
affect cardiac function and contribute to arrhythmogenicity
[43]. Importantly, inhibition of TGFb signaling has been
shown to reduce fibrosis in animal models of cardiac
remodeling and to preserve cardiac function [44, 45].
Besides FMT, TGFb also stimulates epithelial mes-
enchymal transition (EMT) and endothelial mesenchymal
transition (EndoMT) [46, 47]. It has been reported that
approximately 27–35 % of all cardiac fibroblasts in the
pressure-overloaded mouse heart (aortic banding) were
derived from endothelial cells via EndoMT [48]. Inhibition
of EndoMT by infusion of recombinant bone morphogenic
protein-7 (BMP-7) reduced fibrosis in the mouse pressure-
overloaded heart by almost 50 % [48]. Recent cell lineage
tracking studies in mice reported much lower levels of
EndoMT-derived fibroblasts and, moreover, did not pro-
vide a role for enhanced EndoMT during cardiac pressure
overload [49, 50]. Thus, although EndoMT plays an
important role during development of HF [51, 52], the role
for EndoMT in the stressed heart is still controversial.
Circulating bone marrow-derived cells have also been
proposed to be a source of myofibroblasts in the diseased
heart [53, 54], but cell lineage tracking has also disputed
these results [49, 50].
Recently, Kramann et al. [55] identified glioma-associ-
ated oncogene family zinc finger 1 (Gli1) positive
perivascular mesenchymal stem cells (MSCs) as a source
of myofibroblast cells in mouse tissue after induction of
organ damage, including the pressure-overloaded heart
(aortic banding). Interestingly, ablation of these Gli1? cells
reduced cardiac fibrosis by almost 50 %, but also reduced
cardiac hypertrophy and preserved left ventricular ejection
fraction. This nicely exemplifies the importance of myofi-
broblasts in the fibrotic process and in the induction of
pathological hypertrophy. The role of TGFb in the transi-
tion of these Gli1? cells is so far not known.
Thus, although the exact nature of myofibroblasts in the
heart remains obscure, these cells are most likely generated
from resident cell types in the heart. Inhibition of the for-
mation of these myofibroblast populations reduces fibrosis
and improves cardiac function.
Fibrosis impairs cardiac function
Myofibroblast-mediated fibrosis in the myocardium is the
hallmark of pathophysiological cardiac remodeling [13, 14,
18]. In addition to collagens, fibronectin and other struc-
tural ECM proteins, myofibroblasts also express a large
number of matrix remodeling proteins and together deter-
mine the functionality of the ECM. Matrix metallopro-
teases (MMPs) are produced by myofibroblasts and are
secreted as inactive zymogens that can be activated by
cleavage of the propeptide, resulting in active proteases
that can cleave collagens and other ECM proteins [2, 56].
These MMPs are negatively regulated by tissue inhibitors
of metalloproteases (TIMPs), which are also secreted by
myofibroblasts. TIMP1 is the major TIMP in the heart and
is strongly induced in the failing heart [57]. Other matrix
remodeling proteins that are strongly induced in the failing
heart include, among others, lysyl oxidase-like 1 (LOXL1),
latent-transforming growth factor beta-binding protein 2
(LTBP2), Gal-3, connective tissue growth factor (CTGF),
periostin (POSTN), and Serpine2 [58]. Dysregulation of
the proper balance between the different ECM and ECM-
modulating proteins will affect the amount of connective
tissue, its composition and quality, and will affect cardiac
function. Recently, the plasma membrane glycoprotein
syndecan-4 was identified to influence the degree of col-
lagen cross-linking, which ultimately determined the
degree of myocardial stiffness [59]. Syndecan-4 induces
collagen, osteopontin (OPN) and lysyl oxidase (LOX)
expression in cardiac fibroblasts and promotes LOX-de-
pendent cross-linking of collagen fibers [59–61]. Thus,
besides the amount of ECM, the level of collagen cross-
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linking also strongly determines the development of dias-
tolic and systolic dysfunction [9, 16–18, 25, 56, 62].
Fibrosis also disturbs cardiac electrophysiology and
induces rhythm disturbances. In mice, TGFb1 overex-
pression resulted in atrial fibrosis, without ventricular
involvement, and these mice developed inducible atrial
fibrillation (AF) [63, 64]. Also in patients, AF is strongly
associated with atrial fibrosis, [65] and it is now generally
accepted that atrial fibrosis creates a substrate for AF [66,
67]. The mechanism by which myocardial scarring pro-
motes rhythm disturbances is by creating reentry circuits
[9, 16, 18, 62, 68, 69]. Furthermore, function of ion
channels, ion pumps and gap junction proteins is also
disturbed by cardiac remodeling [70]. Thereby, action
potential conduction velocity is reduced which promotes
susceptibility to reentry [70].
Finally, fibrosis limits nutrient supply toward the myo-
cardium by limiting cardiac function and myocardial blood
flow [9]. Perivascular fibrosis in coronary arteries reduces
oxygen delivery toward myocardial tissue, reduces coro-
nary reserves and promotes myocardial ischemia [16, 62].
Moreover, increased ECM deposition, which occurs often
in association with hypertension and thus myocardial
hypertrophy, results in diffusion problems in a situation in
which demand for oxygen and nutrients is increased [14].
As discussed below, (myo)fibroblast also play an important
role in cardiomyocyte hypertrophy development, and
increased cardiomyocyte cell size will reduce oxygen dif-
fusion in the cell interior. Decreased capillary density, as
observed in heart failure tissue, will further contribute to
cardiomyocyte dysfunction and finally cell death [71, 72].
Thus, fibrosis impairs cardiac function by at least three
mechanisms, namely induction of myocardial stiffness,
induction of AF and limiting oxygen and nutrient supply to
the stressed myocardium. This will promote cardiomyocyte
hypertrophy and cell death as schematically depicted in
Fig. 2.
Myofibroblasts and cardiomyocyte hypertrophy
and cell death
Within the myocardium, extensive cross talk between
cardiac fibroblast and cardiomyocytes via soluble factors
and direct cell–cell interactions occurs [27]. Fibroblast–
cardiomyocyte co-cultures and experiments with condi-
tioned medium have shown that paracrine signaling from
fibroblasts induces cardiomyocyte hypertrophy. A number
of cytokines and growth factors, including TGFb, inter-
leukin-33 (IL-33), fibroblast growth factor 2 (FGF2),
tumor necrosis factor alpha (TNFa), insulin growth factor
(IGF1) and endothelin-1 (ET-1), are produced by (myo)
fibroblast, which directly affect cardiomyocyte function
in vitro and/or in vivo [27, 73–79]. Myofibroblasts con-
tribute to the pathological hypertrophic response in car-
diomyocytes via paracrine signaling, which ultimately can
culminate in cardiomyocyte cell death. In mice with a
fibroblast-specific knockout of Kru¨ppel-like factor 5
(Klf5), a transcription factor required for the fibrotic
response, both fibrosis and cardiomyocyte hypertrophy
were strongly ameliorated in the pressure-overloaded
heart. Moreover, pathological cardiomyocyte gene
expression, as exemplified by Nppa expression, was
strongly reduced in these mice [80].
In the last decade, a number of microRNAs (miRs) have
been identified that are increased selectively in fibroblasts
of the failing heart [15, 81]. The TGFb-induced miR-21
inhibits sprouty homologue 1 (Spry1) expression, an
endogenous inhibitor of the ERK-MAPK signaling path-
way. This mechanism is important for fibroblast survival
and for growth factor secretion and controls both the
extend of interstitial fibrosis and cardiomyocyte hypertro-
phy. Silencing of miR-21 by a specific antagomir inhibited
interstitial fibrosis and attenuated cardiomyocyte hyper-
trophy and cardiac dysfunction in a mouse pressure over-
load (transverse aortic constriction, TAC) model [82].
Surprisingly, a miR-21 knockout mouse model did not
show diminished cardiac hypertrophy or fibrosis in
response to pressure overload or angiotensin-2 (AngII)
infusion [83]. This might be explained by compensatory
mechanisms that are activated in the persistent absence of
miR-21, and since HF is a chronic disease, this will likely
limit therapeutic applications targeting miR-21 [83].
Another miR, miR-29, was found to be downregulated in
fibroblasts after MI and controls expression of ECM genes
[84]. Overexpression of miR-29b in the mouse heart pre-
vented AngII-mediated cardiac fibrosis, cardiomyocyte
hypertrophy and cardiac dysfunction [85]. As described
above, myofibroblast depletion, by Gli1 cell ablation, also
attenuated both fibrosis and cardiomyocyte hypertrophy
after aortic banding, resulting in improved cardiac function
[55].
Together these studies provide clear evidence that
myofibroblasts are important drivers of pathological car-
diomyocyte hypertrophy. Hypertrophic stimuli activate
apoptosis signal-regulating kinase 1 (ASK1) in cardiomy-
ocytes in vitro and in vivo, which induces both apoptotic
and necrotic cell death [86, 87]. In ASK1 transgenic mice,
induction of the pro-apoptotic protein Bax was reported
[88]. In a hamster cardiomyopathy model, ASK1 inhibition
by gene transfer of a dominant negative kinase into car-
diomyocytes not only prevented apoptosis, but also
chamber dilation and preserved left ventricular (LV) sys-
tolic and diastolic function. Moreover, cardiac interstitial
fibrosis was significantly inhibited [89]. Cathepsin B
(CTSB), a lysosomal cysteine protease, participates in
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apoptosis and autophagy and is expressed in murine and
human hearts and induced by hypertrophic stimuli [90].
Not surprisingly, knockout of CTSB in mice attenuated
pressure-overload-induced apoptosis, cardiac hypertrophy,
fibrosis and cardiac dysfunction. Deletion of CTSB also
prevented the activation of ASK1 and attenuated the
release of cytochrome c from mitochondria, which has pro-
apoptotic actions in the cytosol [90]. Interestingly, a direct
role for CTSB in matrix remodeling in the eye has been
described via the upregulation and/or proteolytic activation
of ECM-remodeling enzymes [91]. Whether this is also
true in the heart is not known, but it is tempting to spec-
ulate that certain proteins may directly link and coordinate
fibrogenic and cell death processes. Nix, another factor
with pro-apoptotic and necrotic actions in the heart, is
induced by Gaq-mediated hypertrophic stimuli [92, 93].
Cardiac-specific Nix ablation prevented cardiomyocyte
apoptosis and myocardial fibrosis and cardiac decompen-
sation after TAC [94]. A recent co-culture study using adult
rat fibroblasts, myofibroblasts and cardiomyocytes showed
that both fibroblasts and myofibroblasts directly affect
cardiomyocyte cell viability [95]. The TGFBR1 inhibitor
SB341542 prevented this loss of cardiomyocyte viability,
although this was most likely not a direct effect of TGFb. It
has been suggested that this might be mediated via TGFb-
dependent upregulation of ET1 in (myo)fibroblasts. The
latter has been shown to stimulate cardiomyocyte apoptosis
[96]. Thus, myofibroblasts are essential to induce patho-
logical cardiomyocyte hypertrophy that may culminate in
cardiomyocyte cell death via specific cell death signaling
pathways, and, at least in vitro, myofibroblasts can directly
promote cardiomyocyte cell death.
The sustained fibrotic response
In normal wound healing, concomitant disappearance of
myofibroblasts from the tissue marks the termination of the
reparative response [97–100]. In many chronic diseases,
including HF, a sustained fibrotic response is observed that
further culminates in organ damage and finally organ
failure. Apparently, at a certain stage of disease progres-
sion, a point of no return is reached and the fibrotic
response cannot be downregulated anymore by the
endogenous biological systems. The mechanisms behind
this sustained response in the heart are multitude and
include a positive feedback loop of fibroblast proliferation
and FMT, inhibition of myofibroblast apoptosis, car-
diomyocyte-mediated activation of fibroblasts and the
presence of sustained low-grade systemic inflammation, as
outlined below.
TGFb plays an important role in fibroblast proliferation
and FMT, and is produced in high amounts by
myofibroblasts themselves resulting in a positive feedback
loop. TGFb therefore plays a central role in the sustained
fibrotic response in the failing heart. TGFb stimulates
growth factor (EGF, IGF1)-mediated proliferation of
fibroblast, and this probably also involves autocrine sig-
naling via FGF2 and/or connective tissue growth factor
(CTGF) [101, 102]. Inhibition of FGF2-induced fibroblast
proliferation by TGFb has also been described [103],
indicating that this response is strongly dependent on the
exact environmental factors. The increase in fibroblast
numbers in the stressed heart indicates that in vivo this
balance is shifted toward TGFb-mediated fibroblast pro-
liferation [49, 50].
TGFb also prevents myofibroblast apoptosis via stimu-
lation of PI3K/AKT pro-survival signaling pathway, and
this is at least partly mediated via TGFb-mediated secre-
tion of ET1 [104]. The persistence of myofibroblasts can
lead to nonresolving and progressive fibrosis, as exempli-
fied by human idiopathic pulmonary fibrosis (IPF) [105,
106]. In pathological cardiac remodeling, persistent acti-
vation of the TGFb pathway may therefore prevent
myofibroblast apoptosis. This is consistent with the
observation that myofibroblast can have very long life
spans and continue secretion of pro-fibrotic factors and
ECM proteins [107]. In vitro experiments using drugs
targeting the TGFb and MAPK pathways indicate that the
myofibroblast phenotype can be reversed, but whether this
also occurs in vivo and whether it can be stimulated in vivo
is so far not known [108, 109].
In the heart, stressed cardiomyocytes themselves are
important triggers of the fibrotic response of fibroblasts.
Conditional, cardiomyocyte-specific knockout of Kru¨ppel-
like factor 6 (Klf6) in mice resulted in an attenuated
fibrotic response after AngII infusion [110]. Surprisingly, a
fibroblast-specific Klf6 knockout did not show this
response. It was shown that Klf6 in cardiomyocytes con-
trolled the expression of the ECM protein thrombospondin
4 (TSP4), which modulated activation of cardiac fibrob-
lasts. This effect was specific for the AngII response and
was not observed after aortic banding, indicating that under
those conditions other factors are involved. Nevertheless, it
indicates that as long as cardiomyocytes experience stress,
these cells are able to produce factors that can induce and
maintain a fibrotic response.
Inflammation is one of the main drivers of fibrosis and
low-grade but persistent systemic inflammation is present
in HF [111, 112]. Increased levels of cytokines and
inflammatory biomarkers are present in patients, including
TNFa, C-reactive protein (CRP), interleukin-6 (IL-6) and
myeloid peroxidase (MPO), among others [113–117]. The
precise mechanism of systemic inflammation in HF is
unknown, but a growing body of evidence indicates that
inflammation plays a role in the development and
204 Heart Fail Rev (2016) 21:199–211
123
progression of HF and contributes to fibrosis. Cytokines,
such as TNFa and interleukin-1b (IL-1b), are important
activators of a variety of fibrotic diseases including car-
diovascular diseases [118, 119]. TGFb produced by
myofibroblast may also play a role in cardiac inflammation.
TGFb has pleiotropic effects on the immune system and
has both immunosuppressive and pro-inflammatory func-
tions [120]. TGFb can polarize macrophages and neu-
trophils toward a type II phenotype, which produces large
quantities of inflammatory cytokines, including IL-6 and
TGFb. Inflammatory cytokines can activate cell death
pathways and stimulate production of toxic reactive oxy-
gen radicals (ROS) that can further exacerbate cardiac
function. Moreover, systemic inflammation will not only
affect myocardial function, but also other organs and
therefore participate in the full manifestation of the com-
plex HF syndrome [111].
Targeting fibrosis
The above data show that (myo)fibroblasts and fibrosis
adversely affect cardiac function and directly and indirectly
contribute to cardiomyocyte death. This will further
amplify this adverse cycle, leading to more fibrosis and
cardiomyocyte death hereby contributing to HF develop-
ment. Animal studies have shown that cardiac fibrosis
appears not to be an essential stress response under many
circumstances, but does impair cardiac function. Removal
of the fibrotic trigger(s) would therefore constitute a
potential way to halt the progression of cardiac remodeling
and hence provide a cardiac sparing effect and promote
cardiac function. This begs the question whether inhibitors
of fibroblast activation or fibrosis can interfere with the
fibrosis-cell death axis and thereby stop the vicious cycle
which eventually leads to HF. Components of the cycle
that are potential targets to interrupt the fibrosis-cell death
axis are ECM proteins, paracrine and inflammatory signals,
and fibroblasts/myofibroblasts.
By targeting ECM proteins and enzymes, such as
MMPs, LoxL and Gal-3, the production and processing
of collagen can be influenced. Several studies revealed
that MMP inhibition results in less myocardial fibrosis
and improves diastolic function [56, 121]. MMP inhibi-
tion results in less LV dilatation, while collagen accu-
mulation does not occur [56]. Inhibition of LoxL reduces
both the degree of myocardial collagen buildup and
collagen cross-linking and is associated with less LV
dilatation and preserved cardiac function in a mouse
model of MI [122]. Inhibition of Gal-3, a fibrotic HF
marker and a component of the ECM, resulted in less
fibrosis and preserved cardiac function in animal models
of HF [123]. These studies indicate that targeting ECM
proteins holds promise to modulate the fibrotic response
and HF progression.
Blocking paracrine and inflammatory signals can break
the fibrosis-cell death axis as well. Several studies have
investigated the effects of TGFb pathway inhibition on
fibrosis formation. In animal models of MI, early TGFb
receptor inhibition resulted in increased mortality, whereas
late inhibition resulted in reduced fibrosis, improved con-
traction in the infarct zone and improved survival [44]. In
pressure overload models, TGFb receptor inhibition
attenuated cardiac fibrosis and also preserved cardiac
function [44]. However, TGFb receptor inhibitors also
induced valve lesions in animal studies and increased aortic
rupture in a mouse pressure overload model [124, 125].
These TGFb receptor inhibitors may therefore have limited
clinical use for the treatment of chronic diseases. Treat-
ment with pirfenidone, an anti-fibrotic drug for the treat-
ment of IPF, also reduced fibrosis in a pressure overload
mouse model of HF and preserved LV function [45]. The
exact mode of action of pirfenidone is not known, but most
likely interferes with TGFb-induced fibrogenesis [45]. As
revealed from animal studies, interleukin-1 (IL-1) is a
mediator of fibrosis, by recruiting myofibroblasts and
induction ofMMP expression [126]. Clinical trials with IL-1
receptor antagonist treatments in MI patients did, however,
not show beneficial effects on cardiac function [126]. The
latter illustrates that, due to the complexity of cytokine
actions and differences in the exact mechanisms between
species, extrapolation to the human situation is not so
simple.
The discovery of fibroblast-specific microRNAs that
control the fibrotic response opens new avenues to directly
target (myo)fibroblasts [15, 81]. Although constitutive
downregulation of the fibroblast-specific miR-21 resulted
in apparent fibrotic compensatory mechanisms [83],
investigating other miRs could be more rewarding. A
recent study showed that miR-125b is another critical
regulator of cardiac fibrosis [127]. These authors showed
that miR-125b is both necessary and sufficient for the
induction of FMT via targeting of apelin, a critical
repressor of fibrogenesis. In addition, miR-125b inhibited
p53 expression, allowing induction of fibroblast prolifera-
tion. The clinical inhibition of miR-125b may therefore
represent a novel therapeutic approach for the treatment of
human cardiac fibrosis. Rather than downregulating miR
expression using antagomirs or locked nucleic acid (LNA)
oligonucleotides, overexpression of particular miRs should
also be considered. Overexpression of the fibroblast miR-
29b in the mouse heart prevented cardiac fibrosis [85].
Thus, clinical strategies to enhance miR-29b levels in
patients could provide a promising strategy.
Another innovative strategy that holds great promise is
the reprogramming of cardiac myofibroblasts into
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cardiomyocytes [128]. The regenerative capacity of the
heart is thought to be minimal, but by reprogramming
myofibroblasts into cardiomyocytes, the effects of the
fibrosis-cell death axis could be reversed, thereby offering
a curative approach for HF. Song et al. [128] showed that
adult mice fibroblasts could be directly reprogrammed into
cardiac-like myocytes in vitro and in vivo, using the tran-
scription factors GATA4, HAND2, MEF2C and TBX5
(GHMT). Novel cardiomyocytes were indentified in
infarcted areas of mice treated with intramyocardial
injections of GHMT, and preservation of cardiac function
was observed. This same group showed that human
fibroblasts can similarly be reprogrammed in vitro toward a
cardiomyocyte-like fate [129]. Generation of induced car-
diac-like myocytes (iCLMs) could potentially be a
promising new approach to regenerate lost cardiomyocytes
[130]. Nevertheless, numerous technical and biological
hurdles, including efficiency issues and the immature car-
diomyocyte phenotype, need to be overcome.
Discussion
HF is a major health problem in the Western world. Cur-
rently, the therapeutic approach toward HF mainly focuses
on controlling symptoms and unloading the heart by
reducing preload and afterload by treating HF patients with
beta-blockers, angiotensin converting enzyme inhibitors
(ACE-inhibitors), diuretics and aldosterone receptor
antagonists [4, 5]. Although these drugs have shown ben-
eficial effects in terms of relieving symptoms and reducing
mortality [4, 5], prognosis for HF patients remains poor,
with 5- and 10-year mortality rates of 50 and 90 %,
respectively [131]. Current therapy reduces cardiac stress,
but cardiac fibrosis is already present when most patients
present themselves with symptoms at the clinic for the first
time. Targeting the initial triggers, by unloading the heart,
will slow down the vicious fibrosis-cell death cycle.
However, it cannot eliminate the sustained fibrotic
response present in the heart. Therefore, besides targeting
the initial triggers, HF treatment should also focus on
interrupting the fibrosis-cell death axis. As outlined in
Fig. 3, we therefore believe that three pillars are important
in HF therapy, namely unloading the heart, repressing
fibrotic processes and improving cardiomyocyte function.
Several ways to target myofibroblasts and fibrosis have
been discussed above. We did not discuss the numerous
studies that are aimed to improve cardiomyocyte function
or limit cardiomyocyte death. Some interesting approaches
that are under clinical investigation include the upregula-
tion of the sarcoplasmatic reticulum calcium ATPase
(SERCA2a) using gene therapy [132–134] and the use of
myosin activators like omecamtiv mecarbil [135–137].
Whether apoptosis of cardiomyocytes can be inhibited at a
clinical level, using caspase inhibitors or other cell death
inhibitors needs to be awaited [138].
Fig. 3 Suggested three pillars of heart failure treatment. Current
standard heart failure (HF) therapy is focused at relief of the initial
problem and aims at unloading the heart. Upon detection of HF, the
sustained process of cardiac hypertrophy, fibrosis and cardiomyocyte
cell death is already ongoing in most patients and cannot be stopped
without additional treatment. We therefore suggest that to halt this
sustained process, additional therapy will be required that blocks
fibrotic processes and improves cardiomyocyte function. FMT
fibroblasts to myofibroblasts transition, ECM extracellular matrix
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It is difficult to elucidate whether fibrosis or cardiac cell
death should be marked as the driver of the fibrosis-cell
death axis, but it seems likely that both are important
players. However, what can be concluded is that myofi-
broblasts plays a central role in the fibrotic-cell death axis,
by secreting ECM components and autocrine and paracrine
signaling molecules that drive sustained fibrosis, car-
diomyocyte hypertrophy and inflammation. More research
will be needed to identify and test clinical approaches that
can halt this vicious cycle of cardiac fibrosis and cell death
in HF.
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